You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

5346 Results
Regimen
Cancer Type:
Gastrointestinal, 
Rectal
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant
Drugs Used:
oxaliplatin,
leucovorin,
irinotecan,
fluorouracil
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Oct 2025
Regimen
Cancer Type:
Head and Neck, 
Squamous Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative
Drugs Used:
pembrolizumab (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
New
Oct 2025
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - Relapsed or Refractory Multiple Myeloma
New Drug Funding Program
    Daratumumab - In Combination with Bortezomib and Dexamethasone for Relapsed Multiple Myeloma
ODB - General Benefit
    dexamethasone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
daratumumab (subcut),
bortezomib,
dexamethasone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph, Patient Info Sheet
Nov 2024
Drug
Other Name(s): Tibsovo®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Sep 2025
Drug
Other Name(s): Columvi®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Dec 1969
Drug
Other Name(s): Tecvayli®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jul 2025
Drug
Other Name(s): Epkinly™
Quick Link(s):
Drug Monograph, Patient Info Sheet
Nov 2024
Drug
Other Name(s): Kimmtrak®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Dec 1969
Drug
Other Name(s): Ibrance™
Quick Link(s):
Drug Monograph, Patient Info Sheet
Dec 1969
Our Comprehensive Cancer Biomarker Testing Program supports patient management through the testing of diagnostic, predictive and prognostic markers....
Drug
Other Name(s): Truqap™
Quick Link(s):
Drug Monograph, Patient Info Sheet
Updated
Oct 2025
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    capivasertib - For the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, based on criteria
ODB - General Benefit
    fulvestrant
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
capivasertib,
fulvestrant
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Oct 2025

Pages